Skip to main content

Table 1 Clinicopathological description of male breast cancers in this study

From: BRCA2 carriers with male breast cancer show elevated tumour methylation

Feature

Age (years)

Median = 62.5

Range: 30–85

Mutation carrier status

  BRCA1

3

5.0%

  BRCA2

25

41.7%

  BRCAX

32

53.3%

Size (mm)

Median = 17

Range: 2–50

Histological subtype

 Invasive carcinoma - no special type (IC-NST)

46

76.7%

 Invasive papillary carcinoma

8

13.3%

 IC-NST with areas of micropapillary

4

6.7%

 Invasive lobular carcinoma

2

3.3%

Grade

 1

2

3.3%

 2

30

50.0%

 3

28

46.7%

DCIS

 Present

41

68.3%

 Absent

15

25.0%

 Unknown

4

6.7%

Nodal Status

 N0

28

46.7%

 N1

20

33.3%

 Nx

12

20.0%

Paget’s Disease

 Present

8

13.3%

 Absent

44

73.3%

 Unknown

8

13.3%

ER status (Allred score)

  

 Negative (0–4/8)

2

3.3%

 Positive (5–8/8)

58

96.7%

PgR status (allred score)

 Negative (0–4/8)

8

13.3%

 Positive (5–8/8)

52

86.7%

HER2 (SISH)

 Amplified

5

8.3%

 Non-amplified

55

91.7%

Phenotype

 Luminal

54

90.0%

 HER2

5

8.3%

 Basal

1

1.7%